| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8466139 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US8329680 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US6774122 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
| US7456160 | ASTRAZENECA | Formulation |
Jan, 2021
(3 years ago) | |
|
US7456160 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US8466139 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US8329680 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
|
US6774122 (Pediatric) | ASTRAZENECA | Formulation |
Jul, 2021
(2 years ago) | |
Faslodex is owned by Astrazeneca.
Faslodex contains Fulvestrant.
Faslodex has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Faslodex are:
- US8466139
- US8329680
- US6774122
- US7456160
- US7456160*PED
- US8466139*PED
- US8329680*PED
- US6774122*PED
Faslodex was authorised for market use on 25 April, 2002.
Faslodex is available in solution;intramuscular dosage forms.
Faslodex can be used as treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy, treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
The generics of Faslodex are possible to be released after 09 July, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Indication(I-749) | Aug 25, 2020 |
| New Dosing Schedule(D-126) | Sep 09, 2013 |
| M(M-103) | May 17, 2014 |
| Pediatric Exclusivity(PED) | Mar 09, 2014 |
| M(M-123) | Nov 09, 2015 |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 25 April, 2002
Treatment: Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrin...
Dosage: SOLUTION;INTRAMUSCULAR
FASLODEX family patents
